Your Trusted Brand for Over 35 Years

Multiple Sclerosis References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. SOLAR trial. Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR).
  2. Noseworthy, J. H., et al. "Multiple Sclerosis." N Engl J Med 343.13 (2000): 938-52.
  3. Dutta, R., and B. D. Trapp. "Pathogenesis of Axonal and Neuronal Damage in Multiple Sclerosis." Neurology 68.22 Suppl 3 (2007): S22-31; discussion S43-54.
  4. Trapp, B. D., et al. "Axonal Transection in the Lesions of Multiple Sclerosis." N Engl J Med 338.5 (1998): 278-85.
  5. Bjartmar, C., et al. "Neurological Disability Correlates with Spinal Cord Axonal Loss and Reduced N-Acetyl Aspartate in Chronic Multiple Sclerosis Patients." Ann Neurol 48.6 (2000): 893-901.
  6. Lovas, G., et al. "Axonal Changes in Chronic Demyelinated Cervical Spinal Cord Plaques." Brain 123 ( Pt 2) (2000): 308-17.
  7. Smith, E. J., W. F. Blakemore, and W. I. McDonald. "Central Remyelination Restores Secure Conduction." Nature 280.5721 (1979): 395-6.
  8. Compston, A., and A. Coles. "Multiple Sclerosis." Lancet 359.9313 (2002): 1221-31.
  9. Friese, M. A., et al. "The Value of Animal Models for Drug Development in Multiple Sclerosis." Brain 129.Pt 8 (2006): 1940-52.
  10. Goverman, J. "Autoimmune T Cell Responses in the Central Nervous System." Nat Rev Immunol 9.6 (2009): 393-407.
  11. El-Behi, M., et al. "The Encephalitogenicity of T(H)17 Cells Is Dependent on Il-1- and Il-23-Induced Production of the Cytokine Gm-Csf." Nat Immunol (2011).
  12. Goldberg P. Multiple Sclerosis: vitamin D and calcium as environmental determinants of prevalence (a viewpoint). Part 1: sunlight, dietary factors and epidemiology. Intern J Environ Stud 1974, 6: 19-27.
  13. Craelius W. comparative epidemiology of multiple sclerosis and dental caries. J Epidemiol Community Health. 1978 Sep;32(3):155-65.
  14. Tremlett H et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology. 2008;31(4):271-9.
  15. Simpson S Jr. et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010 Aug;68(2):193-203.
  16. Correale J et al. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain. 2009 May;132(Pt 5):1146-60.
  17. Burton JM et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010 Jun 8;74(23):1852-9.
  18. Munger, K. L., et al. "Vitamin D Intake and Incidence of Multiple Sclerosis." Neurology 62.1 (2004): 60-5.
  19. Holick, M. F. "The Vitamin D Epidemic and Its Health Consequences." J Nutr 135.11 (2005): 2739S-48S.
  20. Merlino, L. A., et al. "Vitamin D Intake Is Inversely Associated with Rheumatoid Arthritis: Results from the Iowa Women's Health Study." Arthritis Rheum 50.1 (2004): 72-7.
  21. Ponsonby, A. L., A. McMichael, and I. van der Mei. "Ultraviolet Radiation and Autoimmune Disease: Insights from Epidemiological Research." Toxicology 181-182 (2002): 71-8.
  22. Ponsonby, A. L., R. M. Lucas, and I. A. van der Mei. "Uvr, Vitamin D and Three Autoimmune Diseases--Multiple Sclerosis, Type 1 Diabetes, Rheumatoid Arthritis." PhotochemPhotobiol 81.6 (2005): 1267-75.
  23. Dyment, D. A., G. C. Ebers, and A. D. Sadovnick. "Genetics of Multiple Sclerosis." Lancet Neurol 3.2 (2004): 104-10.
  24. Ebers, G. C., et al. "A Full Genome Search in Multiple Sclerosis." Nat Genet 13.4 (1996): 472-6.
  25. Sawcer, S., et al. "A Genome Screen in Multiple Sclerosis Reveals Susceptibility Loci on Chromosome 6p21 and 17q22." Nat Genet 13.4 (1996): 464-8.
  26. Zhang, Z., et al. "Two Genes Encoding Immune-Regulatory Molecules (Lag3 and Il7r) Confer Susceptibility to Multiple Sclerosis." Genes Immun 6.2 (2005): 145-52.
  27. Gregory, S. G., et al. "Interleukin 7 Receptor Alpha Chain (Il7r) Shows Allelic and Functional Association with Multiple Sclerosis." Nat Genet 39.9 (2007): 1083-91.
  28. Ramagopalan, S. V., et al. "Genomewide Study of Multiple Sclerosis." N Engl J Med 357.21 (2007): 2199-200; author reply 200-1.
  29. Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccines and autoimmune diseases of the adult. Discov Med. 2010 Feb;9(45):90-7.
  30. Fujinami RS, Oldstone MB, Wroblewska Z, et al. Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci U. S. A. 80.8 (1983): 2346-50.
  31. Zabriskie JB. Rheumatic fever: a model for the pathological consequences of microbial-host mimicry. Clin Exp Rheumatol. 1986;4(1):65-73.
  32. Ascherio, A., and K. L. Munger. "Environmental Risk Factors for Multiple Sclerosis. Part I: The Role of Infection." Ann Neurol 61.4 (2007): 288-99.
  33. Lünemann JD, Edwards N, Muraro PA, et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain. 2006 Jun;129(Pt 6):1493-506.
  34. Gelfand JM, Cree BA, McElroy J, Oksenberg J, Green R, MowryEM, Miller JW, Hauser SL, Green AJ. Neurology. Vitamin D in African Americans with multiple sclerosis.2011 May 24;76(21):1824-30.
  35. Pozzilli, C., et al. "Mri in Multiple Sclerosis During the Menstrual Cycle: Relationship with Sex Hormone Patterns." Neurology 53.3 (1999): 622-4.
  36. Hughes, M. D. "Multiple Sclerosis and Pregnancy." NeurolClin 22.4 (2004): 757-69.
  37. Sicotte, N. L., et al. "Treatment of Multiple Sclerosis with the Pregnancy Hormone Estriol." Ann Neurol 52.4 (2002): 421-8.
  38. El-Etr, M., et al. "Steroid Hormones in Multiple Sclerosis." J NeurolSci 233.1-2 (2005): 49-54.
  39. Soldan, S. S., et al. "Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol." J Immunol 171.11 (2003): 6267-74.
  40. Bebo, B. F., Jr., et al. "Gonadal Hormones Influence the Immune Response to Plp 139-151 and the Clinical Course of Relapsing Experimental Autoimmune Encephalomyelitis." J Neuroimmunol 84.2 (1998): 122-30.
  41. Dalal, M., S. Kim, and R. R. Voskuhl. "Testosterone Therapy Ameliorates Experimental Autoimmune Encephalomyelitis and Induces a T Helper 2 Bias in the Autoantigen-Specific T Lymphocyte Response." J Immunol 159.1 (1997): 3-6.
  42. Bansil, S., et al. "Correlation between Sex Hormones and Magnetic Resonance Imaging Lesions in Multiple Sclerosis." ActaNeurolScand 99.2 (1999): 91-4.
  43. Tomassini V, Onesti E, Mainero C, et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J NeurolNeurosurg Psychiatry. 2005 Feb;76(2):272-5.
  44. Landtblom, A. M., et al. "Organic Solvents and Multiple Sclerosis: A Synthesis of the Current Evidence." Epidemiology 7.4 (1996): 429-33.
  45. Riise, T., B. E. Moen, and K. R. Kyvik. "Organic Solvents and the Risk of Multiple Sclerosis." Epidemiology 13.6 (2002): 718-20.
  46. Rodrigo L, Hernández-Lahoz C, Fuentes D, et. al. Prevalence of celiac disease in multiple sclerosis.BMC Neurol. 2011 Mar 7;11:31.
  47. Shor DB, Barzilai O, Ram M Gluten sensitivity in multiple sclerosis: experimental myth or clinical truth? Ann N Y Acad Sci. 2009 Sep;1173:343-9.
  48. Kidd, P. M. "Multiple Sclerosis, an Autoimmune Inflammatory Disease: Prospects for Its Integrative Management." Altern Med Rev 6.6 (2001): 540-66.
  49. Guggenmos J, Schubart AS, et al. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. J Immunol . 2004 Jan 1;172(1):661-8.
  50. Stefferl A, Schubart A, et al. Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. J Immunol. 2000 Sep 1;165(5):2859-65.
  51. Klawiter EC, Piccio L, Lyons JA, Mikesell R, O'Connor KC, Cross AH. Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Arch Neurol. 2010 Sep;67(9):1102-8.
  52. Handel, A. E., et al. "Smoking and Multiple Sclerosis: An Updated Meta-Analysis." PLoS One 6.1 (2011): e16149.
  53. Hedstrom, A. K., et al. "Smoking and Two Human Leukocyte Antigen Genes Interact to Increase the Risk for Multiple Sclerosis." Brain 134.Pt 3 (2011): 653-64.
  54. Hernan, M. A., et al. "Cigarette Smoking and the Progression of Multiple Sclerosis." Brain 128.Pt 6 (2005): 1461-5.
  55. Riise, T., M. W. Nortvedt, and A. Ascherio. "Smoking Is a Risk Factor for Multiple Sclerosis." Neurology 61.8 (2003): 1122-4.
  56. Hartung, H. P., A. Bar-Or, and Y. Zoukos. "What Do We Know About the Mechanism of Action of Disease-Modifying Treatments in Ms?" J Neurol 251 Suppl 5 (2004): v12-v29.
  57. Rao, S. M., et al. "Cognitive Dysfunction in Multiple Sclerosis. I. Frequency, Patterns, and Prediction." Neurology 41.5 (1991): 685-91.
  58. Miller, D., et al. "Clinically Isolated Syndromes Suggestive of Multiple Sclerosis, Part I: Natural History, Pathogenesis, Diagnosis, and Prognosis." Lancet Neurol 4.5 (2005): 281-8.
  59. Virley, D. J. "Developing Therapeutics for the Treatment of Multiple Sclerosis." NeuroRx 2.4 (2005): 638-49.
  60. Yu, M., et al. "Interferon-Beta Inhibits Progression of Relapsing-Remitting Experimental Autoimmune Encephalomyelitis." J Neuroimmunol 64.1 (1996): 91-100.
  61. Heine, S., et al. "Effects of Interferon-Beta on Oligodendroglial Cells." J Neuroimmunol 177.1-2 (2006): 173-80.
  62. Paty, D. W., and D. K. Li. "Interferon Beta-Lb Is Effective in Relapsing-Remitting Multiple Sclerosis. Ii. Mri Analysis Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. 1993 [Classical Article]." Neurology 57.12 Suppl 5 (2001): S10-5.
  63. Ziemssen T, Schrempf  W. “Glatiramer acetate: mechanisms of action in multiple sclerosis.” Int Rev Neurobiol. 79 (2007): 537-70.
  64. Sela, M., and D. Teitelbaum. "Glatiramer Acetate in the Treatment of Multiple Sclerosis." Expert OpinPharmacother 2.7 (2001): 1149-65.
  65. Fox, E. J. "Management of Worsening Multiple Sclerosis with Mitoxantrone: A Review." ClinTher 28.4 (2006): 461-74.
  66. Ransohoff, R. M. "Natalizumab and Pml." Nat Neurosci 8.10 (2005): 1275.
  67. Warnke C, Menge T, Hartung H-P, et al. “Natalizumab and Progressive Multifocal Leukoencephalopathy.” Arch Neurol. 2010;67(8):923-930.
  68. Center Watch. Newly Approved Drug Therapies: Ampyra. Available at: Accessed May 27, 2011.
  69. Nicholas R et al. Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des DevelTher. 2011;5:255-74.
  70. Holmoy T and Celius EG. [Development of new therapies for multiple sclerosis.] Tidsskr Nor Laegeforen. 2011 mai 06;131(8):832-836.
  71. Schilling S, Goelz S, Linker R, et al. “Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration.” Clin Exp Immunol. 145.1 (2006): 101-7.
  72. Shinto, L., et al. "The Perceived Benefit and Satisfaction from Conventional and Complementary and Alternative Medicine (Cam) in People with Multiple Sclerosis." Complement Ther Med 13.4 (2005): 264-72.
  73. Smolders, J., et al. "Vitamin D as an Immune Modulator in Multiple Sclerosis, a Review." J Neuroimmunol 194.1-2 (2008): 7-17.
  74. Wingerchuk DM et al. A pilot study of oral calcitriol (1,25-dihydroxyvitaminD3) for relapsing-remitting multiple sclerosis. J NeurolNeurosurg Psychiatry. 2005 Sep;76(9):1294-6.
  75. Kimball SM. Safety of vitamin D3 in adults with multiple sclerosis. Am J ClinNutr 2007; 86:645-51
  76. Gallai, V., et al. "Cytokine Secretion and Eicosanoid Production in the Peripheral Blood Mononuclear Cells of Ms Patients Undergoing Dietary Supplementation with N-3 Polyunsaturated Fatty Acids." J Neuroimmunol 56.2 (1995): 143-53.
  77. Bates, D., et al. "A Double-Blind Controlled Trial of Long Chain N-3 Polyunsaturated Fatty Acids in the Treatment of Multiple Sclerosis." J NeurolNeurosurg Psychiatry 52.1 (1989): 18-22.
  78. Shinto, L., et al. "Omega-3 Fatty Acid Supplementation Decreases Matrix Metalloproteinase-9 Production in Relapsing-Remitting Multiple Sclerosis." Prostaglandins LeukotEssent Fatty Acids 80.2-3 (2009): 131-6.
  79. Weinstock-Guttman, B., et al. "Low Fat Dietary Intervention with Omega-3 Fatty Acid Supplementation in Multiple Sclerosis Patients." Prostaglandins LeukotEssent Fatty Acids 73.5 (2005): 397-404.
  80. Horrobin, D. F. "Essential Fatty Acids in the Management of Impaired Nerve Function in Diabetes." Diabetes 46 Suppl 2 (1997): S90-3.
  81. Harbige, L. S., and M. K. Sharief. "Polyunsaturated Fatty Acids in the Pathogenesis and Treatment of Multiple Sclerosis." Br J Nutr 98 Suppl 1 (2007): S46-53.
  82. Bates, D., et al. "Trail of Polyunsaturated Fatty Acids in Non-Relapsing Multiple Sclerosis." Br Med J 2.6092 (1977): 932-3.
  83. Paty, D. W., et al. "Linoleic Acid in Multiple Sclerosis: Failure to Show Any Therapeutic Benefit." ActaNeurolScand 58.1 (1978): 53-8.
  84. Dworkin, R. H., et al. "Linoleic Acid and Multiple Sclerosis: A Reanalysis of Three Double-Blind Trials." Neurology 34.11 (1984): 1441-5.
  85. Mai, J., P. S. Sorensen, and J. C. Hansen. "High Dose Antioxidant Supplementation to Ms Patients. Effects on Glutathione Peroxidase, Clinical Safety, and Absorption of Selenium." Biol Trace Elem Res 24.2 (1990): 109-17.
  86. van Meeteren, M. E., et al. "Antioxidants and Polyunsaturated Fatty Acids in Multiple Sclerosis." Eur J ClinNutr 59.12 (2005): 1347-61.
  87. Hadzovic-Dzuvo A et al. Serum total antioxidant capacity in patients with multiple sclerosis. Bosn J Basic Med Sci. 2011 Feb;11(1):33-6.
  88. Arfsten, D., et al. "Impact of 30-Day Oral Dosing with N-Acetyl-L-Cysteine on Sprague-Dawley Rat Physiology." Int J Toxicol 23.4 (2004): 239-47.
  89. Singh, I., et al. "Cytokine-Mediated Induction of Ceramide Production Is Redox-Sensitive. Implications to Proinflammatory Cytokine-Mediated Apoptosis in Demyelinating Diseases." J BiolChem 273.32 (1998): 20354-62.
  90. Gilgun-Sherki, Y., et al. "Analysis of Gene Expression in Mog-Induced Experimental Autoimmune Encephalomyelitis after Treatment with a Novel Brain-Penetrating Antioxidant." J MolNeurosci 27.1 (2005): 125-35.
  91. Ortiz GG, Macías-Islas MA, Pacheco-Moisés FP, et al. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers. 2009;26(1):35-9.
  92. Miller E, Mrowicka M, Zołyński K, Kedziora J. Oxidative stress in multiple sclerosis.2009Dec;27(162):499-502.
  93. Biernacki, K., et al. "Regulation of Cellular and Molecular Trafficking across Human Brain Endothelial Cells by Th1- and Th2-Polarized Lymphocytes." J NeuropatholExpNeurol 63.3 (2004): 223-32.
  94. Cournu-Rebeix, I., et al. "Intercellular Adhesion Molecule-1: A Protective Haplotype against Multiple Sclerosis." Genes Immun 4.7 (2003): 518-23.
  95. Dedrick, R. L., S. Bodary, and M. R. Garovoy. "Adhesion Molecules as Therapeutic Targets for Autoimmune Diseases and Transplant Rejection." Expert OpinBiolTher 3.1 (2003): 85-95.
  96. Marracci, G. H., et al. "Alpha Lipoic Acid Inhibits T Cell Migration into the Spinal Cord and Suppresses and Treats Experimental Autoimmune Encephalomyelitis." J Neuroimmunol 131.1-2 (2002): 104-14.
  97. Morini, M., et al. "Alpha-Lipoic Acid Is Effective in Prevention and Treatment of Experimental Autoimmune Encephalomyelitis." J Neuroimmunol 148.1-2 (2004): 146-53.
  98. Schreibelt, G., et al. "Lipoic Acid Affects Cellular Migration into the Central Nervous System and Stabilizes Blood-Brain Barrier Integrity." J Immunol 177.4 (2006): 2630-7.
  99. Yadav, V., et al. "Lipoic Acid in Multiple Sclerosis: A Pilot Study." MultScler 11.2 (2005): 159-65.
  100. Bonakdar, R. A., and E. Guarneri. "Coenzyme Q10." Am Fam Physician 72.6 (2005): 1065-70.
  101. Siemieniuk, E., and E. Skrzydlewska. "[Coenzyme Q10: Its Biosynthesis and Biological Significance in Animal Organisms and in Humans]." PostepyHig Med Dosw (Online) 59 (2005): 150-9.
  102. Syburra, C., and S. Passi. "Oxidative Stress in Patients with Multiple Sclerosis." UkrBiokhimZh 71.3 (1999): 112-5.
  103. Spindler M, Beal MF, Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat. 2009;5:597-610. Epub 2009 Nov 16.
  104. Reynolds, E. H. "Multiple Sclerosis and Vitamin B12 Metabolism." J Neuroimmunol 40.2-3 (1992): 225-30.
  105. Miller, A., et al. "Vitamin B12, Demyelination, Remyelination and Repair in Multiple Sclerosis." J NeurolSci 233.1-2 (2005): 93-7.
  106. Wade, D. T., et al. "A Randomised Placebo Controlled Exploratory Study of Vitamin B-12, Lofepramine, and L-Phenylalanine (The "CariLoder Regime") in the Treatment of Multiple Sclerosis." J NeurolNeurosurg Psychiatry 73.3 (2002): 246-9.
  107. Birks, J., and J. Grimley Evans. "Ginkgo Biloba for Cognitive Impairment and Dementia." Cochrane Database SystRev.2 (2007): CD003120.
  108. Birks, J., and J. Grimley Evans. "Ginkgo Biloba for Cognitive Impairment and Dementia." Cochrane Database SystRev.1 (2009): CD003120.
  109. Lovera, J., et al. "Ginkgo Biloba for the Improvement of Cognitive Performance in Multiple Sclerosis: A Randomized, Placebo-Controlled Trial." MultScler 13.3 (2007): 376-85.
  110. Aktas, O., et al. "Green Tea Epigallocatechin-3-Gallate Mediates T Cellular Nf-Kappa B Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis." J Immunol 173.9 (2004): 5794-800.
  111. Wong CP, Nguyen LP, Noh SK, Bray TM, Bruno RS, Ho E. Induction of regulatory T cells by green tea polyphenol EGCG. ImmunolLett. 2011 May 20. [Epub ahead of print]
  112. Abe, Y., S. Hashimoto, and T. Horie. "Curcumin Inhibition of Inflammatory Cytokine Production by Human Peripheral Blood Monocytes and Alveolar Macrophages." Pharmacol Res 39.1 (1999): 41-7.
  113. Natarajan, C., and J. J. Bright. "Curcumin Inhibits Experimental Allergic Encephalomyelitis by Blocking Il-12 Signaling through Janus Kinase-Stat Pathway in T Lymphocytes." J Immunol 168.12 (2002): 6506-13.
  114. Xie, L., et al. "Amelioration of Experimental Autoimmune Encephalomyelitis by Curcumin Treatment through Inhibition of Il-17 Production." IntImmunopharmacol 9.5 (2009): 575-81.
  115. Swank, R. L. "Multiple Sclerosis; a Correlation of Its Incidence with Dietary Fat." Am J Med Sci 220.4 (1950): 421-30.
  116. Swank, R. L., and B. B. Dugan. "Effect of Low Saturated Fat Diet in Early and Late Cases of Multiple Sclerosis." Lancet 336.8706 (1990): 37-9.
  117. Sicotte, N. L., et al. "Testosterone Treatment in Multiple Sclerosis: A Pilot Study." Arch Neurol 64.5 (2007): 683-8.
  118. Gold, S. M., et al. "Immune Modulation and Increased Neurotrophic Factor Production in Multiple Sclerosis Patients Treated with Testosterone." J Neuroinflammation 5 (2008): 32.
  119. El-Etr M, Ghoumari A, Sitruk-Ware R, Schumacher M. Hormonal influences in multiple sclerosis: new therapeutic benefits for steroids. Maturitas. 2011 Jan;68(1):47-51. Epub 2010 Oct 29.